Loading…
← CockpitCompetitor Analysis › 688062.SS Mabwell (Shanghai) Bioscience Co., Ltd. Class AOpen in the cockpit ↗

Mabwell (Shanghai) Bioscience Co., Ltd. Class A688062.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese biotech developing monoclonal antibodies and antibody-drug conjugates (ADCs) for cancer and other diseases.

≈ A Chinese ADC-focused biotech, akin to a smaller SeagenMomentum laggard 4
Mkt cap
$1.20B
US dollars, full cap
Free float
92%
of shares outstanding
$/day
$22.6M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-32.5 pp
WACC 9.1%
Hurdle
n/a
no reverse DCF
Next earnings
140 days
7 Apr 2027
Close · CNYCN¥18.50
1D-2.7%
1W-13.9%
1M-18.9%
3M-45.8%
6M-46.1%
YTD-51.9%
1Y-59.8%
ATR %6.5%
52w lowhigh61.3% off high

What Mabwell (Shanghai) Bioscience does

Chinese biotech developing monoclonal antibodies and antibody-drug conjugates (ADCs) for cancer and other diseases.

In one line: A Chinese ADC-focused biotech, akin to a smaller Seagen.

Products and services

  • Monoclonal antibody drugs
  • Antibody-drug conjugate (ADC) pipeline

Customers

  • Hospitals/oncologists

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Monoclonal antibodies & ADCs

What could go right

  • Global ADC licensing/partnership deals

What could go wrong

  • Clinical-trial failure risk
  • Pre-profitability cash burn

Moat: narrow (IP / patents). Patent-protected antibody/ADC pipeline built on in-house biologics R&D.

Headquarters: Shanghai, China · Employees: 1,325

Named competitors

Mabwell (Shanghai) Bioscience at a glance

Size Mabwell (Shanghai) Bioscience (688062.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.20B, the 1849th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥18.50 on 18 Nov 2026.

Performance Over six months the shares fell 46.1%, against -17.3% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue grew 14.9% over the last twelve months (peer median +3.1%); the operating margin is -128.8% (peer median 0.8%).

Valuation It trades at 13.3× enterprise value to sales against a peer median of 7.6× (5th most expensive of 18).

Capital Return on invested capital runs 32.5 points below its cost of capital (9.1% WACC).

Next results Next results expected around 7 Apr 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 85688062.SS 55
Six months, rebased to 100: Mabwell (Shanghai) Bioscience against the median of its 20 peers (local-currency closes).

Mabwell (Shanghai) Bioscience financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥718MCN¥661MCN¥198MCN¥127MCN¥27.7M
Revenue growth—+233%+57%+357%—
Gross profitCN¥594MCN¥387MCN¥39.6MCN¥15.8M-CN¥68.2M
EBITDAn/a-CN¥672M-CN¥885M-CN¥979M-CN¥907M
Net income-CN¥1.05B-CN¥969M-CN¥1.04B-CN¥1.05B-CN¥955M
Free cash flow-CN¥1.04B-CN¥447M-CN¥1.28B-CN¥1.28B-CN¥1.26B
Capital expenditureCN¥107MCN¥158MCN¥330MCN¥500MCN¥545M
Total debtCN¥3.69BCN¥2.97BCN¥2.22BCN¥1.29BCN¥774M

Quarterly statements and history in the cockpit →

Mabwell (Shanghai) Bioscience competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%3000062616HROW688321688443NKTR6855347850IDIA300026000989AVLNGPCR000950GHRS4547300204002550AMPH688062.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Mabwell (Shanghai) Bioscience is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%+200%0×250×500×750×3000062616HROW688443NKTR6855347850688062.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Mabwell (Shanghai) Bioscience is the large dot.

Mabwell (Shanghai) Bioscience competitors and peer comparison

Head to head with its named competitors (688062.SS vs 688331.SS vs 1801.HK)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Mabwell (Shanghai) Bioscience 688062.SS$1.20B-46%+15%-129%13.3×n/a
RemeGen 688331.SS$6.28B-24%+272%61%4.4×1.1%
Innovent Biologics 1801.HK$18.9B+4%+43%17%7.3×11.6%

How Mabwell (Shanghai) Bioscience compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Mabwell (Shanghai) Bioscience against its 20 peers (data as of 18 Nov 2026)
Measure688062.SSPeer medianRank in peer set
1-month return-18.9%-5.1%2nd lowest of 21
6-month return-46.1%-17.3%4th lowest of 21
Distance from 52-week high-61.3%-39.3%5th lowest of 21
Revenue growth (TTM)+14.9%+3.1%7th highest of 18
Operating margin-128.8%0.8%4th lowest of 18
EV / Sales13.3×7.6×5th most expensive of 18
ROIC minus cost of capital-32.5 pp-5.1 pp5th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Mabwell (Shanghai) Bioscience 688062.SSChina$1.20B-46%+15%-129%13.3×n/an/a
Chongqing Lummy Pharmaceutical 300006.SZChina$1.21B+26%-6%-19%10.4×44.1%-13.2%
CStone Pharmaceuticals 2616.HKHong Kong$1.21B-22%+117%-89%17.0×n/an/a
Harrow HROWUnited States$1.21B+4%+21%1%4.7×n/an/a
Shenzhen Chipscreen Biosciences 688321.SSChina$1.18B-38%+27%12%7.6×n/an/a
Chongqing Genrix Biopharmaceutical 688443.SSChina$1.18B-22%+256%-27%8.6×n/an/a
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%13.3×n/an/a
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%13.2×n/an/a
D&D Pharmatech 347850.KSSouth Korea$1.22B-49%-77%-2,324%818.8×n/an/a
Idorsia IDIA.SWSwitzerland$1.22B-9%-5%-70%10.4×n/an/a
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%1.8×7.0%-5.3%
Jiuzhitang 000989.SZChina$1.16B-7%+46%19%2.6×-4.0%-9.0%
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%0.5×n/an/a
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%4.8×3.4%+27.9%
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%1.4×n/an/a
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%39.1×n/an/a
Changzhou Qianhong Bio-Pharma 002550.SZChina$1.14B-12%-2%15%4.2×3.4%-1.2%
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%2.3×2.5%+15.5%

Questions

Who are Mabwell (Shanghai) Bioscience's main competitors?
Named competitors: RemeGen (688331.SS), Innovent Biologics (1801.HK). The cockpit's measured peer set (industry) also includes Chongqing Lummy Pharmaceutical (300006.SZ), CStone Pharmaceuticals (2616.HK), Harrow (HROW), Shenzhen Chipscreen Biosciences (688321.SS), Chongqing Genrix Biopharmaceutical (688443.SS), Nektar Therapeutics (NKTR).
Is Mabwell (Shanghai) Bioscience expensive compared with its peers?
On ev / sales it trades at 13.3× against a peer median of 7.6×, 5th most expensive of 18 in its peer set.
How has Mabwell (Shanghai) Bioscience stock performed?
Over six months to 18 Nov 2026 the shares returned -46.1% against -17.3% for the median peer; over one year -59.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.